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Abstract: Vitamin D deficiency is frequently found in patients with
renal transplants (RTxs). Because vitamin D plays indispensable roles in
the immune system, there may be an association between vitamin D
deficiency and infection in these patients, but this has not been fully
elucidated. Therefore, this study investigated the impact of pre-RTx
vitamin D deficiency on urinary tract infection (UTI) development after
RTx.
We measured 25-hydroxyvitamin D3 (25(OH)D3) levels in 410
patients 2 weeks before they underwent RTx. Vitamin D deficiency was
defined as 25(OH)D3 <10 ng/mL. The primary outcome was UTI
occurrence after RTx. Cox proportional hazard analysis determined
whether vitamin D deficiency was independently associated with
UTI.
The mean 25(OH)D3 level was 12.8 6.9 ng/mL, and 171 patients
(41.7%) were vitamin D deficient. During a median follow-up duration
of 7.3 years, the UTI incidence was significantly higher in vitamin D-
deficient patients (52 patients, 30.4%) compared with vitamin D-non-
deficient patients (40 patients, 16.7%) (P¼ 0.001). Moreover, multi-
variate Cox proportional hazard analysis showed that vitamin D
deficiency was an independent predictor of UTI after RTx (hazard ratio
1.81, 95% confidence interval 1.11–2.97, P¼ 0.02).
Vitamin D deficiency was an independent risk factor for UTI after
RTx; hence, determining 25(OH)D3 levels might help to predict
infectious complications after RTx.
(Medicine 94(9):e594)yu, MD, PhD, Tae- , PhD,
ang, MD, PhD
= confidence interval, ESRD = end-stage renal disease, HR =
hazard ratio, IRB = institutional review board, RTx = renal
transplant, SD = standard deviation, UTI = urinary tract infection,
VDR = vitamin D receptor.
INTRODUCTION
U rinary tract infection (UTI) is the most common infectiouscomplication in renal transplant (RTx) patients. The UTI
incidence in these patients is reportedly between 10% and 98%,
and it is a significant source of posttransplant morbidity.1,2
Previous studies have demonstrated that posttransplant UTI is
associated with posttransplant graft failure and mortality.3,4
Consequently, several studies have determined independent
risk factors for posttransplant UTI, and investigators have
found that being a woman, older age, diabetes mellitus, pro-
longed pretransplantation hemodialysis, cadaveric donors,
acute rejection episodes, excessive immunosuppression, and
urologic problems are significantly associated with UTI after
RTx.4,5
Vitamin D may have pleiotropic effects on various organ
systems that are related to the distribution of the vitamin D
receptor (VDR) throughout the body.6 In addition to its effects
on bone and mineral metabolism, vitamin D plays important
roles in multiorgan systems, including the immune system. The
VDR is expressed on monocytes and macrophages.7 Moreover,
vitamin D promotes macrophage maturation and the secretion
of lysosomal enzyme and hydrogen peroxide, which participate
in macrophages’ antimicrobial activities.8 Vitamin D stimulates
antibacterial peptide expression in monocytes and macro-
phages, including cathelicidin and b-defensin, which are
directly involved in killing intracellular bacteria.9 In addition,
vitamin D induces autophagy, an important process in the
antibacterial response of macrophages toMycobacterium tuber-
culosis.10 Hence, vitamin D deficiency might increase an
individual’s susceptibility to microbial infection. Indeed,
previous studies have shown that vitamin D deficiency is
associated with a higher risk of infection, especially respiratory
tract infection.11,12
As glomerular filtration rates decline, vitamin D concen-
trations decrease proportionally; therefore, most patients with
end-stage renal disease (ESRD) are deficient in or have insuffi-
cient vitamin D.13 Moreover, vitamin D concentrations are
significantly lower in patients with malnutrition,14 which is
prevalent in ESRD patients and is linked to a high risk of
infection. Therefore, infection in ESRD patients might be
attributable to vitamin D deficiencies, but this has not been
extensively explored in these patients.e investigated the impact of serum
(25(OH)D3) concentrations on post-
ment in RTx patients.
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METHODS
Ethics
The institutional review board (IRB) of Yonsei University
Health System Clinical Trial Center approved this study (IRB
No. 4-2014-0366). All patients who participated in this study
were aware of this investigation. However, because this was a
retrospective medical record-based study, and the study subjects
were anonymized, the IRB waived the need for written consent
from the patients.
Patient Selection
We reviewed the medical records of 424 ESRD patients
who received RTx at Yonsei University Health System between
April 2002 and December 2008 and had their 25(OH)D3 levels
measured 2 weeks before they underwent RTx. Among these
patients, 14 were excluded for being aged <18 years (n¼ 1) or
>70 years (n¼ 2), or having a follow-up duration <6 months
(n¼ 11). Thus, the final analysis involved 410 RTx patients
(Figure 1).
Laboratory and Clinical Data
The serum 25(OH)D3 concentrations were determined
using a radioimmunoassay (DiaSorin Inc, Stillwater, MN).
We defined vitamin D deficiency as serum 25(OH)D3 levels
<10 ng/mL (25nmol/L), vitamin D insufficiency as serum
25(OH)D3 levels of 10 to 29 ng/mL (25–72nmol/L), and vitamin
D sufficiency as serum 25(OH)D3 levels 30 ng/mL.14–16
Because only 8 patients had sufficient vitamin D levels, the
patients were divided into group 1 that comprised patients with
serum 25(OH)D3 levels <10ng/mL and group 2 that comprised
patients with serum 25(OH)D3 levels 10ng/mL.
The demographic and clinical data at the time of RTx,
including age, sex, bodymass index (BMI), comorbidities, ESRD
etiology, dialysis modality before RTx, donor type, the season at
the time of RTx, and blood pressure, were recorded. The follow-
ing biochemical laboratory test result data were also collected:
hemoglobin, serum calcium, phosphate, intact parathyroid hor-
mone, alkaline phosphatase, albumin, high-sensitivity C-reactive
protein levels, and white blood cell counts. Furthermore, infor-
mation about the immunosuppressant drugs received and acute
rejection episodes after RTx was retrieved.
Kwon et alFollow-Up and Endpoints
All study participants were regularly assessed at the trans-
plantation clinic, and all UTI events, hospitalizations, and
424 ESRD patients who received
renal transplant in YUHS: 
Check 25 (OH)D3 level 2 wk before
they underwent renal transplant
from April 2002 to December 2008
410 patients formed the study population
Data collection: until February 2014
3 patients were excluded
- Age <18 y (n = 1)
- Age >70 y (n = 2)
11 patients were excluded
- Follow-up duration <6 mo
FIGURE 1. Flow diagram of the study. 25(OH)D3¼25-hydroxy-
vitamin D3, ESRD¼ end-stage renal disease, YUHS¼Yonsei Uni-
versity Health System.
2 | www.md-journal.commortalities were recorded in the events database. Data collection
continued until February 28, 2014. The primary endpoint was
UTI after RTx. A UTI diagnosis was defined as significant
bacteriuria (100,000 colony forming units/mL) on urine
culture with typical symptoms or signs, or fever (>388C)
and typical symptoms or signs without significant bacteriuria.
The typical UTI symptoms or signs included dysuria, frequency,
urgency, cloudy urine, suprapubic pain, pain over the graft, and
costovertebral angle tenderness. The secondary endpoint was
graft failure and all-cause mortality after RTx.
Statistical Analyses
All statistical analyses were performed using IBM SPSS
software version 20 (IBM Corporation, Armonk, NY). Continu-
ous variables are expressed as the means standard deviation
(SD) or as the medians and interquartile ranges for skewed data.
The Kolmogorov–Smirnov test was used to analyze the normal-
ity of the distribution of themeasured parameters, and categorical
variables are expressed as numbers and percentages. The patients
were divided into 2 groups based on their serum 25(OH)D3
concentrations (<10ng/mL and10ng/mL), and the differences
between the groups were analyzed using Student t test or the
Mann–WhitneyU test for continuous variables and the x2 test for
categorical variables. Cumulative survival curves were generated
using the Kaplan–Meier method to determine the impact of
vitamin D deficiency on UTI occurrence, and between-group
survival was compared using a log-rank test. In addition, the
independent prognostic value of vitamin D deficiency in relation
to posttransplant UTI was determined using multivariate Cox
proportional hazards regression analysis, which only included the
variables that were significant in the univariate analysis. P values
<0.05 were considered statistically significant.
RESULTS
Patients’ Baseline Characteristics
Of the 410 RTx patients evaluated, 171 patients (41.7%)
were vitamin D deficient, 231 (56.3%) were vitamin D insuffi-
cient, and 8 (2.0%) had normal serum 25(OH)D3 concentrations
(Table 1). Table 2 presents the patients’ demographic, clinical,
and biochemical data. The meanSD age was 41.1 10.9
years, and 262 patients (63.9%) were men. The meanSD
serum 25(OH)D3 concentration was 12.80 6.90 ng/mL, and
the meanSD serum 25(OH)D3 levels were 6.58 1.94 ng/
mL in group 1 and 17.25 5.60 ng/mL in group 2. No differ-
ences existed between the groups with respect to comorbidities,
ESRD etiologies, donor type, and the immunosuppressive
Medicine  Volume 94, Number 9, March 2015agents administered. However, the dialysis modality before
RTx differed significantly between the groups. The proportion
of hemodialysis patients was significantly higher in group 2
TABLE 1. Prevalence of Vitamin D Deficiency in This Study
Group
Vitamin D Level (25(OH)D3)
Deficiency
<10 ng/mL
Insufficiency
10–29 ng/mL
Sufficiency
30 ng/mL
n, % 171 (41.7) 231 (56.3) 8 (2.0)
25(OH)D3¼ 25-hydroxyvitamin D3.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 2. Baseline Characteristics of the Study Population by Vitamin D Levels
Total
25(OH)D3
P Value(n¼ 410)
Group 1 <10 ng/mL
(n¼ 171)
Group 2 10 ng/mL
(n¼ 239)
Age, y 41.1 10.9 40.8 10.3 41.3 11.3 0.66
Male, % 262 (63.9) 95 (55.6) 167 (69.9) 0.003
BMI, kg/m2 22.4 3.1 22.2 3.0 22.6 3.2 0.30
Smoker, % 107 (26.1) 38 (22.2) 69 (28.9) 0.13
Dialysis vintage, mo 42.3 57.9 35.8 55.7 46.9 59.1 0.06
Follow-up duration, y 7.35 2.41 7.42 2.20 7.30 2.56 0.64
25(OH)D3 level, ng/mL 12.80 6.90 6.58 1.94 17.25 5.60 <0.001
Comorbidities
Hypertension, % 364 (88.8) 155 (90.6) 209 (87.4) 0.31
Diabetes mellitus, % 77 (18.8) 38 (22.2) 39 (16.3) 0.13
Etiology of ESRD 0.17
Diabetes mellitus, % 53 (12.9) 29 (17.0) 24 (10.0) 0.04
Hypertension, % 67 (16.3) 24 (14.0) 43 (18.0) 0.29
Glomerulonephritis, % 117 (28.5) 53 (31.0) 64 (26.8) 0.35
Others, % 27 (6.6) 10 (5.8) 17 (7.1) 0.61
Unknown, % 146 (35.6) 55 (32.2) 91 (38.1) 0.22
Pretransplantation treatment modality <0.001
Preemptive, % 88 (21.5) 50 (29.2) 38 (15.9) 0.22
Hemodialysis, % 210 (51.2) 50 (29.2) 160 (66.9) <0.001
Peritoneal dialysis, % 78 (19.0) 57 (33.3) 21 (8.8) <0.001
Previous kidney transplantation, % 34 (8.3) 14 (8.2) 20 (8.4) 0.95
Donor type 0.51
Living-related donor, % 226 (55.1) 100 (58.5) 126 (52.7) 0.25
Living-unrelated donor, % 97 (23.7) 38 (22.2) 59 (24.7) 0.56
Deceased donor, % 87 (21.2) 33 (19.3) 54 (22.6) 0.42
Seasons (transplantation) <0.001
Spring (March–May) 90 (22.0) 51 (29.8) 39 (16.3) 0.001
Summer (June–August) 107 (26.1) 29 (17.0) 78 (32.6) <0.001
Autumn (September–November) 101 (24.6) 37 (21.6) 64 (26.8) 0.23
Winter (December–February) 112 (27.3) 54 (31.6) 58 (24.3) 0.10
Acute rejection episode, % 62 (15.1) 17 (9.9) 45 (18.8) 0.02
Immunosuppressive therapy
Steroids, n (%) 401 (97.8) 168 (98.2) 233 (97.5) 0.61
Cyclosporine, n (%) 185 (45.1) 81 (47.4) 104 (43.5) 0.44
Tacrolimus, n (%) 212 (51.7) 85 (49.7) 127 (53.1) 0.49
Mycophenolate mofetil, n (%) 283 (69.0) 117 (68.4) 166 (69.5) 0.82
Mizoribine, n (%) 54 (13.2) 17 (9.9) 37 (15.5) 0.10
Laboratory data
White blood cell count, 103/mL 6.83 2.39 6.53 2.16 7.05 2.52 0.03
C-reactive protein, mg/L 0.15 (0.00–0.68) 0.13 (0.00–0.68) 0.19 (0.00–0.68) 0.88
Albumin, g/dL 4.1 0.5 3.9 0.5 4.2 0.5 <0.001
Hemoglobin, g/dL 10.2 1.8 9.6 1.9 10.5 1.6 <0.001
Calcium, mg/dL 8.0 1.3 7.7 1.2 8.3 1.3 <0.001
Phosphate, mg/dL 5.5 1.6 5.2 1.5 5.7 1.7 0.001
Calcium phosphate, mg2/dL2 44.6 15.8 40.1 13.3 47.8 16.7 <0.001
Intact parathyroid hormone, pg/mL 148.23 (60.9–308.3) 152.4 (68.7–292.7) 147.0 (55.3–321.4) 1.00
Alkaline phosphatase, IU/L 67.5 53.0 66.2 43.4 68.4 59.0 0.68
nter
Medicine  Volume 94, Number 9, March 2015 Vitamin D Deficiency and UTI After RTx(66.9%) compared with group 1 (29.2%) (P< 0.001), and
significantly more patients were on peritoneal dialysis in group
All data are expressed as mean standard deviations or medians and i
index, ESRD¼ end-stage renal disease.1 (33.3%) compared with group 2 (8.8%) (P< 0.001). Signifi-
cantly more patients in group 2 (32.6%) underwent RTx in
summer compared with group 1 (17.0%) (P< 0.001), whereas
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.more patients in group 1 (29.8%) underwent RTx in spring
compared with group 2 (16.3%) (P¼ 0.001). Acute rejection
quartile ranges. 25(OH)D3¼ 25-hydroxyvitamin D3, BMI¼ body massepisodes were more frequent in group 2 (18.8%) than in group 1
(9.9%) (P¼ 0.02). Hemoglobin, serum calcium, and albumin
concentrations were significantly lower in group 1 compared
www.md-journal.com | 3
with group 2 (P< 0.001) (Table 2). Serum levels of intact
parathyroid hormone and alkaline phosphatase did not differ
significantly between the groups.
Outcomes
During the median follow-up period of 7.3 years, post-
transplant UTI was significantly more prevalent in patients with
vitamin D deficiencies (52 patients, 30.4%) compared with
patients without vitamin D deficiencies (40 patients, 16.7%)
(P¼ 0.001), and the follow-up periods were comparable
between the groups. Additionally, we compared the occurrence
of early UTI, which developed within 6 months from RTx, and
there was no difference between the groups (group 1, 4.7% vs
group 2, 2.9%, P¼ 0.35). The frequency of UTI events during
follow-up was calculated, and 68.6 UTI events per 1000 patient-
years occurred in group 1 and 33.8 UTI events per 1000 patient-
years occurred in group 2. Graft failure and patient mortality
did not differ significantly between the groups (Table 3). The
Kaplan–Meier curves showed that UTI-free survival rates were
significantly lower in vitamin D-deficient patients (P¼ 0.001)
(Figure 2). Additionally, we apportioned the patients into
tertiles according to their serum 25(OH)D3 levels to compare
the incidence of UTI among the 3 groups, which were defined
as follows: tertile 1, 25(OH)D3<8.5 ng/mL; tertile 2, 8.5
25(OH)D315.1; and tertile 3, 25(OH)D3> 15.1 ng/mL.
The incidence of UTI after RTx was 33.8% in tertile 1,
21.9% in tertile 2, and 11.7% in tertile 3 (Figure 3).
Risk Factors for Posttransplant UTI
Cox proportional hazards regression analysis determined
the independent risk factors for posttransplant UTI develop-
ment. Univariate Cox regression analysis determined that vita-
min D deficiency (hazard ratio [HR] 1.99; 95% confidence
interval [CI] 1.32–3.00, P¼ 0.001), being a woman (HR 7.19,
95% CI 4.48–11.56, P< 0.001), BMI (HR 0.92, 95% CI 0.86–
0.98, P¼ 0.01), smoking (HR 0.31, 95% CI 0.16–0.60,
P¼ 0.001), and a deceased donor (HR 1.79, 95% CI 1.13–
2.85, P¼ 0.01) were statistically significant factors associated
with posttransplant UTI. Multivariate Cox regression analysis
determined that vitamin D deficiency was independently associ-
ated with posttransplant UTI after adjusting for gender, BMI,
smoking status, and donor type (HR 1.56, 95% CI 1.03–2.38,
Kwon et alP¼ 0.04).When the variables clinically associated with vitamin
D deficiency, including age, pre-RTx dialysis modality, hemo-
globin, and serum albumin concentrations, and the season at the
TABLE 3. Outcomes According to Baseline 25(OH)D3 Levels
Group 1 <10 ng/m
UTI, n (%) 52 (30.4
Early UTI, n (%)

8 (4.7)
Late UTI, n (%)

45 (26.3
Frequency of UTI events/1000 patient-years 68.6
Graft failure, n (%) 7 (4.1)
Mortality, n (%) 4 (2.3)
25(OH)D3¼ 25-hydroxyvitamin D3, RTx¼ renal transplant, UTI¼ urina
UTI events were classified as early (within 6months fromRTx) and late (a
had both early and late UTI events.
4 | www.md-journal.comtime of the RTx, were included in the multivariate model,
vitamin D deficiency remained an independent risk factor for
posttransplant UTI (HR 1.81, 95% CI 1.11–2.97, P¼ 0.02)
(Table 4).
DISCUSSION
Vitamin D plays an important role in the antimicrobial
action of macrophages, but its impact on UTI has not been
extensively explored in RTx patients. In this study, the preva-
lence of vitamin D deficiency was extremely high among
Korean ESRD patients at the time of RTx. Furthermore, we
demonstrated that vitamin D deficiency was an independent
predictor of posttransplant UTI in these patients.
Vitamin D deficiency is prevalent in not only ESRD
patients but also the general population.17,18 Almost all ESRD
patients are vitamin D deficient because of reduced mobility
and sun exposure, defects in skin synthesis, malnutrition, and
increases in vitamin D catabolism. Sadlier and Magee15 found
that vitamin D deficiency (28.6%) and insufficiency (58.9%)
were prevalent in 112 ESRD patients at the time of RTx.
However, an Australian study of 257 patients who were about
to undergo kidney or kidney–pancreas transplantations showed
that serum 25(OH)D3 levels <10 ng/mL were present in only
6% of the patients.19 In this study, vitamin D deficiency was
present in 41.7% of the patients, which was significantly higher
compared with the results from previous studies. Old age, being
a woman, diabetes, peritoneal dialysis, malnutrition, winter, and
high latitudes are associated with low serum vitamin D con-
centrations in ESRD patients. Hence, it is unclear why the
proportion of vitamin D-deficient ESRD patients was rather
high at the time of RTx in this study, but poor dietary and
supplementary vitamin D intakes, sunscreen use, and the dislike
of ultraviolet B radiation in Korea may contribute to this
phenomenon. An international epidemiological study investi-
gated 2589 community-dwelling, postmenopausal women with
osteoporosis from 18 countries to determine the risk factors for
vitamin D insufficiency.17 Interestingly, Korean participants
had the lowest mean serum vitamin D levels (17.6 ng/mL), and
>85% and 95% of the participants had vitamin D insufficiency
(<30 ng/mL) in summer and winter, respectively, which sup-
ports the results of this study.
Vitamin D exerts its calciotropic action by binding to VDR
Medicine  Volume 94, Number 9, March 2015in the intestine, parathyroid gland, and bones, thereby increas-
ing calcium reabsorption in the small intestine, suppressing the
synthesis and secretion of parathyroid hormone, and enhancing
25(OH)D3
P ValueL (n¼ 171) Group 2 10 ng/mL (n¼ 239)
) 40 (16.7) 0.001
7 (2.9) 0.35
) 36 (15.1) 0.005
33.8
9 (3.8) 0.87
11 (4.6) 0.23
ry tract infection.
fter 6 months fromRTx). One patient in group 1 and 3 patients in group 2
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
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Medicine  Volume 94, Number 9, March 2015calcium resorption in the bone.7 However, accumulating evi-
dence suggests that VDRs are distributed throughout the body,
and that they are present within the brain, cardiac muscle,
kidney, prostate, breast, lymphocytes, and macrophages,
suggesting that vitamin D plays important roles in these organs
and tissues, in addition to its roles in calcium homeostasis and
bone metabolism.6 Several laboratory investigations have
shown that vitamin D controls multiple genes that are involved
in cellular proliferation, differentiation, and apoptosis. Further-
more, numerous clinical studies have demonstrated that vitamin
D deficiency is associated with different chronic diseases,
including colorectal, prostate, breast, and pancreatic cancers,
multiple sclerosis, systemic lupus erythematosus, diabetes,
hypertension, congestive heart failure, myocardial infarction,
and depression.20–25
Vitamin D is a potent immunomodulator, and it prevents
macrophages from releasing too many inflammatory cytokines
FIGURE 2. UTI-free survival rates based on vitamin D levels.
UTI¼urinary tract infection.and chemokines,26 promotes their maturation and lysosomal
enzyme secretion, and their production of antimicrobial pep-
tides, including cathelicidin and b-defensin.27 Cathelicidin and
In
ci
de
nc
e 
of
 U
TI
, %
Tertile 1 Tertile 2
25 (OH)D3 levels, ng/mL
P < 0.001
Tertile 3
Tertile 1: <8.5 ng/mL
Tertile 2: 8.5–15.1 ng/mL
Tertile 3: >15.1 ng/mL
0
10
20
30
40
FIGURE 3. Incidence of UTIs among the tertiles based on vitamin
D levels. 25(OH)D3¼25-hydroxyvitamin D3, UTI¼urinary tract
infection.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.b-defensin are also synthesized and secreted by cells other than
macrophages, including airway and urogenital epithelial
cells.28,29 Moreover, these peptides inactivate influenza virus,
suggesting that they also have antiviral properties.30 Human and
mouse urinary tract epithelial cells produce cathelicidin, and
bacterial contact with epithelial cells results in the rapid
production and secretion of cathelicidin.31 In vivo experiments
using cathelin-related antimicrobial peptide-deficient and
neutrophil-depleted mice showed that epithelially derived
cathelicidin substantially contributed to the protection of the
urinary tract against infection, suggesting that cathelicidin is a
key factor in the mucosal immunity of the urinary tract.31 After
the cathelicidin and b-defensin gene promoters were shown to
contain vitamin D response elements, it was inferred that
vitamin D could reinforce host defenses by inducing these
peptides. Although vitamin D coadministered with a commer-
cially available influenza vaccine failed to enhance humoral
immunity in 175 human subjects, the coadministration of
vitamin D with a trivalent influenza vaccine augmented muco-
sal and systemic antibody responses in mice.32 Moreover, the
activation of Toll-like receptors, which trigger direct antimi-
crobial activity against intracellular bacteria, upregulated VDR
and vitamin D-1-hydroxylase expression in human macro-
phages, inducing cathelicidin production and killing intracellu-
lar M tuberculosis.33 Based on these findings, vitamin D
deficiency may increase susceptibility to microbial infection,
but this has not been extensively explored in RTx patients. The
results from this study found, for the first time, that vitamin D
deficiency was independently associated with a higher UTI risk
in RTx patients. Furthermore, the independent predictive value
of vitamin D deficiency and being a woman for post-RTx UTI
remained significant, even after adjusting for donor type, which
has been shown to be independently associated with post-RTx
UTI development. Unfortunately, we did not determine cathe-
licidin and b-defensin expression in the 2 groups; hence, it was
difficult to clarify whether the UTI risk was attributable to
defects in the antimicrobial peptides of the urogenital epi-
thelium or macrophages, or other factors.
UTI is the most common infectious complication after
RTx, accounting for 40% to 50% of all infectious compli-
cations. It is also responsible for about 30% of the sepsis in
RTx patients.2 Early UTI was often associated with acute
pyelonephritis and bacteremia, and these could be complicated
by acute rejection and the patients’ morbidity and mortality.1
However, some studies debated whether late UTI had an impact
on graft and patient outcomes.34,35 In the present study, UTI was
more prevalent in patients with vitamin D deficiency, but there
was no difference between the 2 groups in relation to early UTI
occurrence (patients with vitamin D deficiency 4.7%, patients
without vitamin D deficiency 2.9%, P¼ 0.35). However, there
was no difference in all-cause mortality and graft failure
between the 2 groups because of a limited number of mortality
and graft failure cases with limited follow-up duration. Further
studies with a longer follow-up duration are needed to deter-
mine the impact of frequent late UTI on graft failure and
mortality in vitamin D-deficient patients.
There are several limitations to this study. First, because all
of the subjects were Korean ESRD patients, the associations
between vitamin D and post-RTx UTI may not extend to other
populations. Further studies will be necessary to clarify the
relationship of vitamin D deficiency with UTI in patients with
Vitamin D Deficiency and UTI After RTxother chronic diseases as well as in the general population.
Second, serum vitamin D concentrations were only measured
once; therefore, it is difficult to elucidate whether serum vitamin
www.md-journal.com | 5
TABLE 4. Multivariate Cox Regression Analysis for the Incidence of UTIs With Adjustments for Various Factors
Model 1 Model 2
HR (95% CI) P Value HR (95% CI) P Value
Vitamin D deficiency (vs 10 ng/mL) 1.56 (1.03–2.38) 0.04 1.81 (1.11–2.97) 0.02
Female (vs male) 6.58 (3.74–11.56) <0.001 6.79 (3.85–11.96) <0.001
BMI (per 1 kg/m2) 1.00 (0.93–1.07) 0.94 1.00 (0.93–1.08) 0.95
Smoker (vs nonsmoker) 0.99 (0.46–2.13) 0.98 0.97 (0.45–2.10) 0.94
Donor 0.10 0.19
Living-related donor Reference Reference
Living-unrelated donor 1.16 (0.69–1.95) 0.57 1.19 (0.69–2.05) 0.52
Deceased donor 1.71 (1.04–2.80) 0.03 1.64 (0.96–2.80) 0.07
Age (per 1 y increase) — — 1.00 (0.98–1.02) 0.99
Albumin (per 1 g/dL decrease) — — 1.23 (0.75–2.03) 0.42
Hemoglobin (per 1 g/dL decrease) — — 0.96 (0.84–1.10) 0.58
Seasons 0.70
Spring — — 0.75 (0.40–1.42) 0.38
Summer — — Reference
Autumn — — 0.75 (0.40–1.39) 0.36
Winter — — 0.95 (0.53–1.70) 0.86
Pretransplantation treatment mode 0.67
Preemptive — — Reference
Hemodialysis — — 1.44 (0.76–2.72) 0.26
Peritoneal dialysis — — 1.10 (0.55–2.18) 0.79
Previous kidney transplantation — — 1.51 (0.56–4.07) 0.42
od
Kwon et al Medicine  Volume 94, Number 9, March 2015D level changes had any influence on post-RTx UTI develop-
ment. Third, even though some previous studies showed that
1,25-dihydroxyvitamin D3 (1,25[OH]2D3) correlated more
accurately with estimated glomerular filtration rate than
25(OH)D3,36,37 only 25(OH)D3 levels were used to determine
vitamin D status in the current study. The reasons are as follows:
25(OH)D3 has a longer half-life of 3 weeks than 1,25(OH)2D3
of 4 hours.38,39 In addition, a single measurement of
1,25(OH)2D3 levels does not represent vitamin D storage status
correctly because of its high variability, whereas 25(OH)D3 has
been validated in many studies as a reliable marker of vitamin D
status.11,12,15,18,40 Moreover, we focused on the impact of
vitamin D deficiency on UTI development in RTx patients
rather than the correlation between vitamin D levels and renal
function. Fourth, because asymptomatic UTI cannot be detected
by physicians, the post-RTx UTI prevalence might be under-
estimated. Fifth, even though serious urologic problems were
not present at the time of RTx, the data on newly developed
urologic abnormality or the duration of catheter indwelling
during the follow-up period after RTx were not clearly avail-
able. Lastly, even though standard dietary advice including
balanced nutritional intake and essential vitamin supplement
was provided to all patients close to the time of discharge after
RTx, there was still a possibility that individual difference in not
only dietary habits but also sunlight exposure after RTx had
some influences on the results of the current study.
In conclusion, vitamin D deficiency was prevalent among
ESRD patients undergoing RTx, and it was an independent risk
factor for post-RTx UTI, suggesting that determining
Model 1: vitamin D deficiency, sex, BMI, smoking, donor type; M
BMI¼ body mass index, CI¼ confidence interval, HR¼ hazard ratio.25(OH)D3 levels might predict infectious complications after
RTx. Further studies are needed to verify the association
between vitamin D deficiency and infection risk after RTx
6 | www.md-journal.comby examining the effects of vitamin D replacement in these
patients.
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